Improving Oral Decitabine Bioavailability with Cedazuridine

Decitabine is a critical DNA hypomethylating agent used for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Traditionally, its poor oral decitabine bioavailability required patients to undergo frequent intravenous infusions. However, the development of a fixed-dose combination with cedazuridine has revolutionized treatment options. This oral medication achieves systemic exposure equivalent to intravenous therapy by preventing the rapid degradation of decitabine in the digestive system and liver.

The Dual Mechanism of Action

While clinicians primarily attribute the boost in oral decitabine bioavailability to the inhibition of cytidine deaminase (CDA), recent research suggests a more complex interaction. Cedazuridine effectively blocks first-pass metabolism in the gut and liver, where CDA usually degrades decitabine. Furthermore, new evidence shows that cedazuridine influences renal elimination. By interacting with the concentrative nucleoside transporter 1 (CNT1) in the kidneys, cedazuridine reduces the renal clearance of decitabine. Consequently, this dual mechanism ensures more consistent and higher drug levels in the bloodstream, mimicking the effects of a continuous infusion.

Implications for Clinical Practice

Understanding these pharmacokinetic drivers is essential for optimizing patient outcomes in hematological care. The interplay between CDA inhibition and renal transporter modulation highlights why this combination is so effective. Additionally, it provides a scientific framework for predicting potential drug-drug interactions involving renal transport pathways. As more oral therapies enter the oncology space, these insights will help clinicians manage treatment protocols more precisely for patients in India and worldwide.

Frequently Asked Questions

Why is decitabine usually given intravenously?

Decitabine has very poor oral decitabine bioavailability on its own because the enzyme cytidine deaminase (CDA) quickly breaks it down in the digestive tract and liver before it reaches the bloodstream.

How does cedazuridine change the way decitabine is absorbed?

Cedazuridine acts as a potent CDA inhibitor, protecting decitabine from early degradation. It also affects renal transporters like CNT1, which helps maintain therapeutic levels of the drug by reducing its loss through urine.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional clinical judgment or direct patient care. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan. Refer to the latest local and national guidelines for clinical practice.

References

1. Anabtawi N et al. Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability. Cancer Res Commun. 2026 Mar 02. doi: 10.1158/2767-9764.CRC-25-0764. PMID: 41770597.


2. Garcia-Manero G, et al. Oral decitabine-cedazuridine vs intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. Lancet Haematol. 2024;11(1):e15-e26.


3. FDA. INQOVI (decitabine and cedazuridine) tablets, for oral use. Prescribing Information. 2020.